摘要
目的评估心肌钙蛋白I(CTnI)对接受含蒽环类方案化疗的乳腺癌患者心脏毒性的预测价值。方法收集186例在南方医院接受含蒽环类方案化疗的乳腺癌患者的病案资料,记录患者化疗前和每个化疗周期CTnI浓度及化疗前和首次化疗开始后第2、4、6月的左心室射血分数(LVEF)。据文献报道,当患者血清CTnI≥0.1ng/ml时,心脏毒性发生率明显升高,据此我们将患者定义为两组,化疗期间血清CTnI≥0.1ng/ml者为CTnI+组(60例),小于0.1ng/ml者为CTnI-组(126例)。结果所有患者均未出现充血性心力衰竭(CHF)。LVEF较化疗前下降幅度超过10%的患者CTnI+组出现16例,占26.7%(16/60),而CTnI-组出现7例,占5.6%(7/126),两组间有统计学差异(P<0.01)。结论 CTnI可作为早期预测蒽环类化疗药物引起心脏毒性的指标。
Objective To evaluate the value of cardiac troponin I （CTnI） measurement in predicting anthracycline-induced cardiotoxicity in patients with breast cancer. Methods This study was conducted among 186 breast cancer patients receiving anthracycline-based chemotherapy. Serum cTnI concentrations before and after each cycle of the chemotherapy and the left ventricular ejection fraction （LVEF） before and at the 2nd, 4th and 6th months of the treatment were recorded. According to serum cTnI concentration, the patients were divided into CTnI＋ group （with serum CTnI concentration of no less than 0.1 ng/ml, n=60） and CTnI- （〈0.1 ng/ml） group （n=126）. Results No patients in this series experienced cardiac heart failure （CHF）. The number of patients with a LVEF reduction by over 10% from the baseline was 16 （26.7%） in CTnI＋ group, as compared to 7 （5.6%） in CTnI- group, showing a significant difference between the two groups （P〈0.01）. Conclusion CTnI can be a useful marker for early prediction of anthracycline-induced cardiotoxicity in patients with breast cancer
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2011年第6期1047-1050,共4页
Journal of Southern Medical University
基金
广东省科技计划项目(2003C34206)
关键词
心肌钙蛋白I
蒽环类
心脏毒性
乳腺癌
cardiac troponin I
anthracycline
cardiotoxicity
breast cancer
